Top Page
Zimmer Biomet Holdings
(NYSE:ZBH)
Zimmer Biomet Holdings (ZBH) vs. SPDR S&P 500 ETF (SPY)
Zimmer Biomet Holdings Business Overview & Revenue Model
Zimmer Biomet Holdings Key Performance Indicators (KPIs)
Zimmer Biomet Holdings Earnings Call Summary
Zimmer Biomet Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.01B | 7.68B | 7.39B | 6.94B | 6.83B | 6.13B |
| Gross Profit | 5.72B | 5.49B | 5.31B | 4.92B | 4.87B | 4.30B |
| EBITDA | 2.38B | 2.25B | 2.22B | 1.49B | 1.65B | 1.01B |
| Net Income | 805.20M | 903.80M | 1.02B | 231.40M | 401.60M | -138.90M |
Balance Sheet | ||||||
| Total Assets | 23.49B | 21.37B | 21.50B | 21.07B | 23.46B | 24.42B |
| Cash, Cash Equivalents and Short-Term Investments | 1.29B | 525.50M | 415.80M | 375.70M | 378.10M | 802.10M |
| Total Debt | 8.11B | 6.20B | 5.77B | 5.70B | 7.07B | 8.13B |
| Total Liabilities | 10.72B | 8.89B | 9.01B | 9.04B | 10.79B | 12.22B |
| Stockholders Equity | 12.76B | 12.47B | 12.48B | 12.02B | 12.66B | 12.19B |
Cash Flow | ||||||
| Free Cash Flow | 1.60B | 1.14B | 1.19B | 1.07B | 1.35B | 1.09B |
| Operating Cash Flow | 1.69B | 1.50B | 1.58B | 1.28B | 1.50B | 1.20B |
| Investing Cash Flow | -1.94B | -888.10M | -778.90M | -529.20M | -503.60M | -613.80M |
| Financing Cash Flow | 982.40M | -484.50M | -763.50M | -843.80M | -1.31B | -421.80M |
Zimmer Biomet Holdings Technical Analysis
Zimmer Biomet Holdings Risk Analysis
Zimmer Biomet Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $148.27B | 53.50 | 12.66% | ― | 21.62% | 54.80% | |
79 Outperform | $48.39B | 35.50 | 13.59% | ― | 0.19% | 65.58% | |
71 Outperform | $118.26B | 25.46 | 9.72% | 3.06% | 4.98% | 22.08% | |
70 Outperform | $136.15B | 46.75 | 14.04% | 0.94% | 10.95% | -18.32% | |
69 Neutral | $14.12B | 29.39 | 9.20% | 2.26% | 5.78% | 61.52% | |
65 Neutral | $17.54B | 21.90 | 6.41% | 1.08% | 5.47% | -23.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Zimmer Biomet Holdings Corporate Events
Study Overview: Zimmer Biomet Holdings is conducting a randomized controlled trial titled ‘Randomized Controlled Trial to Compare Persona OsseoTi Keel Cementless TKA vs Persona Keel Cemented TKA.’ The study aims to evaluate the safety, performance, and clinical benefits of both cementless and cemented knee systems, which is significant for improving treatment options for various knee conditions.
The Persona OsseoTi Keel Compatibility Study, officially titled ‘Persona® OsseoTi® Keel Compatibility Study-A Multicenter Cohort Study,’ is a prospective, post-market clinical follow-up study. Its main goal is to assess the safety, performance, and clinical benefits of the Persona Knee System Portfolio and its instrumentation in primary total knee arthroplasty. This study is significant as it aims to provide valuable insights into the effectiveness of these knee implants in treating various knee conditions, including chronic knee pain, osteoarthritis, and rheumatoid arthritis.
Zimmer Biomet Holdings is conducting a clinical study titled ‘Clinical Investigation to Demonstrate Performance, Safety and Clinical Benefits of the Persona Revision Knee System.’ The study aims to evaluate the performance, safety, and clinical benefits of the Persona Revision Knee System in patients undergoing primary or revision total knee arthroplasty. This research is significant as it seeks to improve outcomes for patients with knee complications, infections, and osteoarthritis.
Study Overview: Zimmer Biomet Holdings is conducting a multicenter, prospective post-market clinical follow-up study titled ‘G7 Freedom Constrained Vivacit-E Liners.’ The study aims to confirm the long-term safety, performance, and clinical benefits of these liners in primary and revision total hip arthroplasty, which is significant for improving patient outcomes in conditions like osteoarthritis and hip fractures.
Zimmer Biomet Holdings is currently conducting a post-market clinical follow-up study titled ‘JuggerStitch™ for Meniscal Repair Post Market Clinical Follow-up Study.’ The primary aim of this study is to confirm the safety and performance of the JuggerStitch Device, which is used for meniscal repair. This study is significant as it seeks to validate the device’s effectiveness in treating meniscus tears and lesions, ensuring it meets the product’s labeling standards.
Study Overview: Zimmer Biomet Holdings has initiated a clinical study titled Multicenter, Post-Market Clinical Follow-up Study of the Z1 Femoral Hip System. The study aims to confirm the safety, performance, and clinical benefits of the Z1 Femoral Hip System in hip arthroplasty procedures. The primary focus is on assessing the implant’s safety by tracking its survival rate two years post-implantation, along with recording any revisions, complications, and adverse events. Secondary objectives include evaluating functional performance through patient-reported outcomes.
Study Overview: Zimmer Biomet Holdings is conducting a study titled Concordance Between an App-based Range of Motion Measurement and Standard Goniometer. The study aims to evaluate how well the mymobility knee ROM app measures knee range of motion compared to traditional clinician assessments using a goniometer. This research is significant as it could validate a more accessible, app-based method for assessing knee mobility.
Study Overview: Zimmer Biomet Holdings is conducting a clinical study titled ‘Comprehensive Segmental Revision System’ to evaluate the performance and clinical outcomes of their Comprehensive Segmental Revision System. This study is significant as it aims to address conditions such as degenerative disease, oncology, revision surgery, trauma, and rheumatoid arthritis, providing valuable insights into the effectiveness of this medical device.
Study Overview: Zimmer Biomet Holdings is conducting a study titled Post-Market Clinical Follow-Up Study of the Vivacit-E Vitamin E Highly Crosslinked Polyethylene HXLPE Elevated Liners in Primary THA- A Retrospective Enrollment/Prospective Follow-Up Study. The study aims to confirm the long-term safety, performance, and clinical benefits of the Vivacit-E Vitamin E HXLPE Elevated Liners in primary total hip arthroplasty, which is significant for improving patient outcomes in hip replacement surgeries.
Study Overview: Zimmer Biomet Holdings is conducting the Persona IQ Cohort Study, a multicentric prospective cohort study aimed at evaluating the safety, functional performance, and effectiveness of the Persona IQ® Personalized Knee System integrated with the mymobility® Care Management Application. The study seeks to develop correlative measures to aid surgeons in managing patient recovery post-total knee arthroplasty by analyzing kinematic metrics captured through advanced sensors.
Zimmer Biomet Holdings is conducting a Post-market Clinical Follow-up (PMCF) study titled ‘Post-market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data of the Anatomical Shoulderᵀᴹ 2.0 Fracture System.’ The study aims to gather long-term data on the safety, performance, and clinical benefits of the Anatomical Shoulder 2.0 Fracture System used in shoulder arthroplasty. The primary focus is on safety, specifically implant survivorship, while secondary objectives include performance and clinical benefits through patient-reported outcomes and radiographic data.
Study Overview: Zimmer Biomet Holdings is conducting a post-market clinical follow-up study titled ‘Post-market Clinical Follow-up Study to Collect Safety, Performance and Clinical Benefits of the ComposiTCP™ Suture Anchors Double Loaded With BroadBand Tape, Sliding.’ The study aims to collect data on the safety, performance, and clinical benefits of these suture anchors when used in rotator cuff repair, with a focus on healing, functional outcomes, and safety.
Study Overview: Zimmer Biomet Holdings is conducting a study titled ‘Post-market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data of the Comprehensive® Primary Revision Stems.’ The study aims to gather long-term data on the safety, performance, and clinical benefits of Comprehensive Primary Revision Stems used in shoulder arthroplasty over periods of 1, 3, 5, 7, and 10 years. This research is significant as it seeks to validate the effectiveness and safety of these medical devices in treating various shoulder conditions.
Study Overview: The study titled ‘A Multi-Center, Prospective Post-Market Clinical Follow-Up Study: Subscapularis Repair Augmented With Tapestry Biointegrative Implant After Shoulder Arthroplasty Evaluation (RAISE)’ aims to assess the long-term integrity of subscapularis tendon repair post shoulder arthroplasty. Conducted by Zimmer Biomet, its primary focus is on evaluating the tendon repair’s integrity using ultrasound six months post-surgery, alongside secondary objectives like assessing shoulder function, safety, and patient-reported outcomes.
Zimmer Biomet Holdings is conducting a Post-Market Clinical Follow-Up (PMCF) study titled ‘Post-Market Clinical Follow-Up Study to Provide Safety, Performance and Clinical Benefits Data of the RingLoc Bipolar Acetabular Cup or Endo II Heads (Implants and Instrumentation) in Hip Hemiarthroplasty.’ The study aims to gather data on the safety, performance, and clinical benefits of the RingLoc Bipolar Acetabular Cup and Endo II Femoral Heads used in hip hemiarthroplasty, addressing conditions such as hip arthritis and fractures.
Study Overview: The Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study aims to confirm the safety, performance, and clinical benefits of the Zimmer Biomet Shoulder Arthroplasty systems. This multicenter, prospective, non-controlled study focuses on primary anatomic shoulder arthroplasty, assessing safety through adverse event monitoring and evaluating performance through pain, function, quality of life, and radiographic assessments.
Study Overview: Zimmer Biomet Holdings is conducting a global, multi-center, prospective post-market clinical follow-up study titled Global, Multicenter and Prospective Post-Market Clinical Follow-Up Study of the G7® Dual Mobility Acetabular System With Vivacit-E® or Longevity® Poly Bearing & Instrumentation. The study aims to confirm the long-term safety, performance, and clinical benefits of the G7 Dual Mobility Acetabular System in primary total and revision hip arthroplasty.
Study Overview: Zimmer Biomet Holdings is conducting a global, multicenter, and prospective post-market clinical follow-up study titled Global, Multicenter, and Prospective Post-Market Clinical Follow-Up Study of the G7 Acetabular System With Vivacit-E and Longevity Highly Crosslinked Polyethylene (HXLPE) Liners & Instrumentation. The study aims to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with Vivacit-E and Longevity HXLPE liners in both primary and revision total hip arthroplasty. This research is significant as it seeks to validate the effectiveness of these components in improving patient outcomes in hip replacement surgeries.
Study Overview: Zimmer Biomet Holdings is conducting a study titled ‘Post-market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data of the Comprehensive Versa-Dial Reverse Titanium (Ti) Glenosphere in Primary, Fracture and Revision Total Shoulder Arthroplasty.’ The study aims to gather data on the safety and performance of the Comprehensive Versa-Dial Reverse Ti Glenosphere, a device used in shoulder arthroplasty, to meet EU Medical Device and other regulatory requirements.
Study Overview: Zimmer Biomet Holdings is conducting a study titled ‘Evaluation of Hi-Fatigue G Bone Cement With Gentamicin A Retrospective Data Collection.’ The study aims to gather data on the safety, performance, and clinical benefits of Hi-Fatigue G Bone Cement used in hip and knee arthroplasties. This research is significant as it seeks to confirm the product’s effectiveness and safety through retrospective data analysis.
Study Overview: Zimmer Biomet Holdings is conducting a post-market clinical follow-up study titled ‘Post Market Clinical Follow-up Study on the Refobacin Revision-3 Bone Cement and Its Instrumentation’. The study aims to confirm the safety, performance, and clinical benefits of Refobacin Revision-3 Bone Cement in knee or hip revision surgeries. It will focus on the removal of metal components, adverse events, pain and functional performance, quality of life, and radiographic parameters.
Zimmer Biomet Holdings has announced a new pilot study, officially titled A Single-arm, Monocentric, Cross-sectional, Pilot Study Evaluating Updated Features for The ROSA® Knee System, v1.5, in Patients Undergoing Primary Total Knee Arthroplasty. The study aims to assess the initial safety and usability of new features in the ROSA® Knee System, v1.5, focusing on intra-operative complications, device performance, and surgeon satisfaction. This research is significant for advancing robotic-assisted knee surgery technologies.
Zimmer Biomet Holdings is conducting a study titled Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study. The study aims to confirm the safety, performance, and clinical benefits of the Zimmer Biomet Shoulder Arthroplasty Systems in treating various shoulder conditions. It focuses on assessing outcomes through standard scoring systems, radiographic evidence, and monitoring adverse events.
Zimmer Biomet Holdings is conducting a Post Market Clinical Follow-up (PMCF) study titled ‘Post Market Clinical Follow up Study to Provide Safety, Performance and Clinical Benefits Data of the Taperloc Complete Stems.’ The study aims to gather data on the safety, performance, and clinical benefits of the Taperloc Complete Stems used in total hip arthroplasty procedures, with follow-ups at 1, 3, 5, 7, and 10 years. This study is significant as it seeks to validate the long-term effectiveness of these implants.
Study Overview: Zimmer Biomet Holdings is conducting a study titled A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee. The study aims to evaluate the performance of the Vanguard 360 revision knee system, focusing on mechanical alignment restoration, clinical outcomes, and survivorship. This research is significant for improving knee replacement outcomes in patients with various forms of arthritis and limb deformities.
Zimmer Biomet Holdings is conducting a study titled ‘Comprehensive Reverse Shoulder Clinical Outcomes Study’ to evaluate the effectiveness of the Biomet Comprehensive Reverse Shoulder system. The study aims to assess improvements in pain scores one year post-surgery and gather long-term clinical outcomes for patients with shoulder conditions such as osteoarthritis and rheumatoid arthritis.
Study Overview: Zimmer Biomet Holdings is conducting a clinical study titled ‘Retrospective and Prospective Clinical Outcomes Study of the Zimmer® Nexel™ Total Elbow.’ The study aims to confirm the safety and performance of the Zimmer Nexel Total Elbow in primary or revision total elbow replacement, addressing conditions like elbow joint destruction and advanced rheumatoid arthritis.
Study Overview: Zimmer Biomet Holdings is conducting a study titled ‘Collection of CT Images to Evaluate Bone Quality Before Total Shoulder Arthroplasty.’ The study aims to assess preoperative bone quality using CT scans to develop a decision-making scale for stemless shoulder arthroplasty. This research is significant for improving surgical outcomes in patients with shoulder osteoarthritis and rotator cuff tears.
Study Overview: Zimmer Biomet Holdings is conducting a study titled ‘Post-market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data of the Biomet Cannulated Bone Screw System.’ The study aims to confirm the safety, performance, and clinical benefits of the Biomet Cannulated Bone Screw System when used as per approved indications. This research is significant as it seeks to ensure the continued reliability and effectiveness of these medical devices in treating bone fractures.
Zimmer Biomet Holdings is conducting a study titled ‘ROSA Knee Intraoperative Planning Flexibility on Japan Preferred Surgical Technique, a Single Center Prospective Study.’ The study aims to assess the effectiveness of the ROSA Knee System, a robotic surgical assistant, in providing intraoperative adjustments during total knee arthroplasty (TKA) based on real-time feedback from soft tissue conditions. This research is significant as it could enhance surgical precision and outcomes for patients with osteoarthritis and rheumatoid arthritis.
Zimmer Biomet Holdings is conducting a study titled ‘Performance, Safety and Clinical Benefits of a Noble Metal Alloy-coated Intramedullary Nail: a Multicenter, Prospective Trial With a Retrospective Control.’ The study aims to compare fracture-related infection rates between the ZNN Bactiguard Tibia and conventional uncoated titanium-alloy nails 12 months post-tibia fracture fixation. It also seeks to confirm the safety, performance, and clinical benefits of the ZNN Bactiguard implant.
Zimmer Biomet Holdings is conducting a study titled ‘Post-market Clinical Follow-up Study of the ExploR™ Radial Head System (Implants and Instrumentation) – A Retrospective Enrollment/Prospective Follow-Up Consecutive Series Study.’ The study aims to gather long-term data on the safety, performance, and clinical benefits of the ExploR Radial Head System, specifically used in radial head arthroplasty for elbow injuries.
Zimmer Biomet Holdings is conducting a post-market clinical follow-up study titled Post-Market Clinical Follow-up Study on the ZNN™ Bactiguard ® Retrograde Femoral Nails (Implants and Instrumentation). The primary aim is to confirm the safety, performance, and clinical benefits of the ZNN Bactiguard Retrograde Femoral Nails used for temporary internal fixation and stabilization of femoral fractures. This study is significant as it seeks to validate the effectiveness of these devices in real-world settings.
Zimmer Biomet Holdings is conducting a clinical study titled ‘A.L.P.S. Clavicle Plating System for Clavicle Fracture Fixation Post-Market Follow-up Study.’ The study aims to confirm the safety, performance, and clinical benefits of the A.L.P.S. Clavicle Plating system, focusing on both the implant and the surgical instrumentation used. This research is significant as it seeks to validate the effectiveness of a commercially available product in treating clavicle fractures.
Study Overview: Zimmer Biomet Holdings is conducting a study titled ‘PMCF Study to Provide Safety, Performance and Clinical Benefits Data of the Comprehensive Segmental Revision System (SRS) Regenerex Tissue Attachment Augments – A Retrospective Enrollment and Prospective Follow-up Consecutive Series Study.’ The study aims to confirm the safety, performance, and clinical benefits of the Comprehensive SRS Regenerex Tissue Attachment Augments, particularly in limb salvage arthroplasty, addressing complications such as arthroplasty complications and osteoarthritis in shoulders.
Zimmer Biomet Holdings is conducting a study titled ‘Post-Market Clinical Follow-Up Study to Provide Safety, Performance and Clinical Benefits Data of the XtraFix® Small External Fixation System.’ The primary aim is to confirm the safety and performance of the XtraFix® system in treating long bone fractures, with a focus on fracture healing and the incidence of complications.
On October 7, 2025, Zimmer Biomet Holdings completed the acquisition of Monogram Technologies, an AI-driven orthopedic robotics company. This strategic move aims to expand Zimmer Biomet’s portfolio by integrating Monogram’s semi- and fully autonomous robotic technologies, enhancing their offerings in orthopedic procedures. The acquisition is expected to strengthen Zimmer Biomet’s position in the industry by providing surgeons with a broader choice of robotic and navigation solutions, thereby accelerating innovation and supporting long-term growth.
The most recent analyst rating on (ZBH) stock is a Hold with a $104.00 price target. To see the full list of analyst forecasts on Zimmer Biomet Holdings stock, see the ZBH Stock Forecast page.
On September 4, 2025, Zimmer Biomet Holdings issued two series of senior unsecured debt securities in Swiss francs, totaling CHF 600 million. These bonds, maturing in 2030 and 2035, feature interest rates of 0.930% and 1.560% respectively, and include provisions for redemption and repurchase under certain conditions, impacting the company’s financial strategy and stakeholder interests.
The most recent analyst rating on (ZBH) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Zimmer Biomet Holdings stock, see the ZBH Stock Forecast page.
Zimmer Biomet Holdings recently held its second-quarter earnings call, revealing a generally positive sentiment characterized by strong quarterly performance and increased revenue in key segments. The company expressed optimism about future growth driven by strategic acquisitions and product launches, although it acknowledged challenges such as international order delays, tariff impacts, and decreased operating margins.
Zimmer Biomet Holdings, Inc., a leading global medical technology company, specializes in providing innovative solutions to enhance mobility and improve health through its comprehensive portfolio of orthopedic and surgical products, including integrated digital and robotic technologies.